ASweetLife Team
Abbott logo

Glucose Test Strips Recalled: Risk of False Low Blood Glucose Results

Abbott Diabetes Care and the FDA have recalled 359 different lots of glucose test strips marketed under the following brand names: Precision Xceed Pro, Precision Xtra, Medisense Optium, Optium, OptiumEZ and ReliOn Ultima. The problem with these strips relates to a defect that inhibits sufficient absorption of blood into the test strip. Strips exposed to warm weather or prolonged storage may be more likely to provide a false result...
0 Shares
TEVA

Teva To Market a Generic Version of ACTOS in 2012

Takeda Pharmaceutical Company Limited has granted Teva Pharmaceutical Industries Ltd. a license to market a generic version of ACTOS® in the U.S. beginning on August 17, 2012, and a generic version of ACTOplus met® beginning December 14, 2012. The license was granted following an agreement to settle patent litigation related to Teva's generic versions of Takeda's ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl) in the United States...
0 Shares
NovoNordiskLogo

Novo Nordisk to Develop Oral Insulin

Novo Nordisk has announced the signing of an exclusive Development and Licence Agreement with Emisphere Technologies, Inc. to develop and commercialize oral formulations ofNovo Nordisk’s insulins. This is the second license agreement between the two companies. The first agreement for the development of oral formulations of GLP-1 receptor agonists was signed...
0 Shares

Sanofi-aventis Acquires Next Generation Drug Delivery Technology for Diabetes Treatment

Sanofi-aventis announced it has signed a global licensing and patent transfer agreement with Ascendis Pharma (Ascendis) on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect...
0 Shares
Amylin logo

Amylin Submits Initial Sections of Rolling Biologics License Application for Metreleptin

Amylin Pharmaceuticals, Inc. announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy. Consistent with the severity and rare nature of the disorder...
0 Shares
living_cell_technologies_Logo

Russia First Country to Approve Porcine Islet Cell Transplants

Living Cell Technologies announced that its Russian subsidiary, LCT Biomedical Limited, has received registration of the company’s groundbreaking diabetes treatment, DIABECELL, as a marketable medical technology in Russia. Registration allows for the sale and use of the DIABECELL technology in the treatment of type 1 diabetes in Russia....
0 Shares
Novo Nordisk Logo

Charlie Kimball, Type 1 Diabetic, To Pilot New IndyCar Entry

Novo Nordisk announced today that it has joined Chip Ganassi Racing to create the Novo Nordisk Chip Ganassi Racing team for the 2011 IZOD IndyCar season. The team will sponsor a new entry in the series driven by American racecar driver and type 1 diabetic, Charlie Kimball...
0 Shares

Almonds May Prevent Type 2 Diabetes

A recent study shows that incorporating almonds into your diet can help treat and possibly prevent type 2 diabetes.The study, published in the June 2010 Journal of the American College of Nutrition, is one of the first of its kind to quantify prevention data...
0 Shares
Medtronic - logo

Medtronic Launches New Diabetes Software Following FDA Approval

Medtronic announced the market launch of CareLink®Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. This announcement was made following the Food and Drug Administration approval of the software for diabetes management support...
0 Shares